Claims for Patent: 8,716,264

Summary for Patent: 8,716,264

Title:	Compositions and methods for combination antiviral therapy
Abstract:	The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread.RTM.) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)- -pyrimidin-2-one (emtricitabine, Emtriva.TM., (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.
Inventor(s):	Dahl; Terrence C. (Sunnyvale, CA), Menning; Mark M. (San Francisco, CA), Oliyai; Reza (San Carlos, CA)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Application Number:	12/204,174
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,716,264
Patent Claims:	1. A chemically stable fixed-dose combination comprising 300 mg of tenofovir disoproxil fumarate and 200 mg of emtricitabine wherein the combination exhibits less than 10% degradation of the tenofovir disoproxil fumarate and emtricitabine after six months at 40.degree. C./75% relative humidity when packaged and stored with silica gel desiccant at 40.degree. C./70% relative humidity. 2. The chemically stable combination of claim 1 in the form of a pharmaceutical dosage form. 3. The chemically stable combination of claim 2 wherein the dosage form is oral. 4. The pharmaceutical dosage form of claim 2 wherein the tenofovir disoproxil fumarate is not substantially degraded. 5. The pharmaceutical dosage form of claim 4 where there is less than 10% degradation of tenofovir disoproxil fumarate over a 24-hour period. 6. The pharmaceutical dosage form of claim 4 where there is less than 1% degradation of tenofovir disoproxil fumarate over a 24-hour period. 7. The pharmaceutical dosage form of claim 4 where there is less than 0.1% degradation of tenofovir disoproxil fumarate over a 24-hour period. 8. The pharmaceutical dosage form of claim 4 where there is less than 0.01% degradation of tenofovir disoproxil fumarate over a 24-hour period. 9. The pharmaceutical dosage form of claim 2 wherein less than 5% degradation of the tenofovir disoproxil fumarate and emtricitabine occurs after six months. 10. A chemically stable fixed-dose combination comprising 300 mg of tenofovir disoproxil fumarate and 200 mg of emtricitabine wherein the combination exhibits less than 10% degradation of tenofovir disoproxil fumarate over a 24-hour period. 11. The chemically stable combination of claim 10, in the form of a pharmaceutical dosage form. 12. The chemically stable combination of claim 11, wherein the dosage form is oral. 13. The pharmaceutical dosage form of claim 11, wherein there is less than 1% degradation of tenofovir disoproxil fumarate. 14. The pharmaceutical dosage form of claim 11, wherein there is less than 0.1% degradation of tenofovir disoproxil fumarate. 15. The pharmaceutical dosage form of claim 11, wherein there is less than 0.01% degradation of tenofovir disoproxil fumarate. 16. The pharmaceutical dosage form of claim 11, wherein the combination exhibits less than 10% degradation of the tenofovir disoproxil fumarate and emtricitabine after six months at 40.degree. C./75% relative humidity when packaged and stored with silica gel desiccant at 40.degree. C./70% relative humidity. 17. The pharmaceutical dosage form of claim 11 wherein the combination exhibits less than 5% degradation of the tenofovir disoproxil fumarate and emtricitabine after six months at 40.degree. C./75% relative humidity when packaged and stored with silica gel desiccant at 40.degree. C./70% relative humidity. 18. The pharmaceutical dosage form of claim 2 or 11 comprising 300 mg tenofovir disoproxil fumarate, 200 mg emtricitabine, pregelatinized starch, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, and magnesium stearate. 19. The pharmaceutical dosage form of claim 18 comprising 300 mg tenofovir disoproxil fumarate, 200 mg emtricitabine, 50 mg pregelatinized starch, 60 mg croscarmellose sodium, 80 mg lactose monohydrate, 300 mg microcrystalline cellulose, and 10 mg magnesium stearate. 20. The pharmaceutical dosage form of claim 18 comprising 300 mg tenofovir disoproxil fumarate, 200 mg emtricitabine, 50 mg pregelatinized starch, 60 mg croscarmellose sodium, 180 mg lactose monohydrate, 200 mg microcrystalline cellulose, and 10 mg magnesium stearate. 21. The pharmaceutical dosage form of claim 2 or 11 comprising 300 mg tenofovir disoproxil fumarate, 200 mg emtricitabine, pregelatinized starch, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, magnesium stearate, and colloidal silicon dioxide. 22. The pharmaceutical dosage form of claim 21 comprising 300 mg tenofovir disoproxil fumarate, 200 mg emtricitabine, 50 mg pregelatinized starch, 60 mg croscarmellose sodium, 175 mg lactose monohydrate, 200 mg microcrystalline cellulose, 10 mg magnesium stearate, and 5 mg colloidal silicon dioxide. 23. The pharmaceutical dosage form of claim 21 comprising 300 mg tenofovir disoproxil fumarate, 200 mg emtricitabine, hydroxypropyl methylcellulose, lactose B.P., pregelatinized starch B.P, and magnesium stearate. 24. The pharmaceutical dosage form of claim 21 comprising 300 mg tenofovir disoproxil fumarate, 200 mg emtricitabine, 112 g hydroxypropyl methylcellulose, 53 mg lactose B.P., 28 mg pregelatinized starch B.P, and 7 mg magnesium stearate. 25. The pharmaceutical dosage form of claim 2 or 11 comprising less than 1% of impurities related to tenofovir disoproxil fumarate and emtricitabine. 26. The pharmaceutical dosage form of claim 2 or 11, further comprising a third anti-viral agent. 27. The pharmaceutical dosage form of claim 26, wherein the third antiviral agent is selected from the group consisting of protease inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and integrase inhibitors. 28. The pharmaceutical dosage form of claim 27, wherein the third antiviral agent is a protease inhibitor. 29. The pharmaceutical dosage form of claim 27, wherein the third antiviral agent is a nucleoside reverse transcriptase inhibitor. 30. The pharmaceutical dosage form of claim 27, wherein the third antiviral agent is a non-nucleoside reverse transcriptase inhibitor. 31. The pharmaceutical dosage form of claim 27, wherein the third antiviral agent is an integrase inhibitor. 32. The pharmaceutical dosage form of claim 30, wherein the third antiviral agent is efavirenz. 33. A method for the treatment of the symptoms or effects of an HIV infection in an infected animal which comprises administering to said animal the pharmaceutical dosage form of claim 2 or 11. 34. A method for the treatment of the symptoms or effects of an HIV infection in an infected animal which comprises administering to said animal the pharmaceutical dosage form of claim 9 or 13. 35. A method for the treatment of the symptoms or effects of an HIV infection in an infected animal which comprises administering to said animal the pharmaceutical dosage form of claim 21. 36. A method for the treatment of the symptoms or effects of an HIV infection in an infected animal which comprises administering to said animal the pharmaceutical dosage form of claim 26. 37. A method for the treatment of the symptoms or effects of an HIV infection in an infected animal which comprises administering to said animal the pharmaceutical dosage form of claim 27. 38. A method for the treatment of the symptoms or effects of an HIV infection in an infected animal which comprises administering to said animal the pharmaceutical dosage form of claim 32.